Leverkusen, Germany (pta036/21.07.2022/16:25) - Deutsche Balaton AG, headquartered in Heidelberg, Germany, announced its decision to make a voluntary public takeover offer for all shares of Biofrontera AG on June 07, 2022. It published the offer document on July 15, 2022. The offer document was transmitted to Biofrontera AG by Deutsche Balaton AG on July 20, 2022.
In the meantime, Biofrontera AG has received various inquiries from shareholders regarding the takeover offer and the offer document. Biofrontera AG therefore points out that the Management Board and the Supervisory Board of Biofrontera AG will issue a statement on the takeover offer as well as on each of its amendments pursuant to Section 27 WpÜG.
The publication of the statement will take place on the internet at https://www.biofrontera.com/ in the section "INVESTORS" presumably by August 01, 2022.
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Leverkusen-based company develops and markets innovative products for the treatment, protection and care of the skin. Its key products include Ameluz®, a prescription drug for the treatment of non-melanoma skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the USA since May 2016. In Europe, the company also markets the Belixos® dermocosmetic series, a specialty care product for damaged skin. Biofrontera is one of a few German pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on US OTC market (BFAGY). www.biofrontera.com
Forward-looking statements: Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as "anticipate", "believe", "predict", "estimate" and "intend", among others. Such forward-looking statements are based on current estimates and assumptions made by Biofrontera AG's management to the best of its knowledge and belief, which in their opinion are reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, financial condition, performance or achievements of the company or industry to be materially different from any future results, financial condition, performance or achievements expressed or implied by such forward-looking statements. No undue reliance should be placed on such statements. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statements.(end)
Hemmelrather Weg 201
|Contact Person:||Investor Relations|
|Phone:||+49 (0) 214 87 63 20|
|Stock Exchanges:||regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate|
|Other Stock Exchanges:||US OTC|